The biotech company ALA Diagnostics joins the GAEM Accelerator
The GAEM Foundation, headquartered in the Barcelona Science Park, has incorporated into the GAEM Accelerator the company ALA Diagnostics, which seeks to develop a diagnostic kit for multiple sclerosis, less invasive than currently available, to reduce costs and the time necessary to detect this disease suffered by more than 55,000 people in Spain.
The early diagnosis of multiple sclerosis (MS) is a fundamental factor in designing an effective treatment that reduces the symptoms of MS and improves the quality of life of affected people. The first results of the ALA Diagnostics EM KIT are promising, since the test would allow diagnosing the disease using a quick, cheap and effective blood test.
ALA Diagnostics has several innovative elements in its multiple sclerosis detection process, which make it an ideal project for the GAEM Accelerator. The biotech company uses a specific blood biomarker, a recombinant protein under patent, which, combined with its diagnostic algorithm, allows the MS detection process to be introduced into the clinical routine of any medical consultation, public or private.
Currently, a new case of multiple sclerosis is detected every 5 hours in Spain, in total, 1,800 cases per year. Despite this, the diagnosis remains expensive, invasive and slow on many occasions, due to the nature of the disease. That is why projects like ALA Diagnostics are necessary, which will mean an improvement in the quality of life of thousands of people.
The GAEM Foundation will promote the project, collaborating in the search for financing and contributing its experience in the acceleration of research projects in multiple sclerosis. The ALA Diagnostics team prepares to market its diagnostic kit within 24 months.